+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Orphan Drug"

Rare Diseases Market Report 2023-2033 - Product Thumbnail Image

Rare Diseases Market Report 2023-2033

  • Report
  • February 2023
  • 290 Pages
  • Global
From
From
Global Market for Contract Research Organization (CRO) Services - Product Thumbnail Image

Global Market for Contract Research Organization (CRO) Services

  • Report
  • December 2021
  • 109 Pages
  • Global
From
From
Innovations in Drug Discovery and Development - Product Thumbnail Image

Innovations in Drug Discovery and Development

  • Report
  • March 2018
  • 15 Pages
  • Global
From
Tofersen Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Tofersen Emerging Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
Reldesemtiv Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Reldesemtiv Emerging Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
PrimeC Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

PrimeC Emerging Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
From
From
From
VTX-801 Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

VTX-801 Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
UX701 Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

UX701 Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
ALXN1840 Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

ALXN1840 Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
Loading Indicator

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them. The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives. Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more